Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer

PSA-ACT is as useful as total PSA for identifying patients with a low probability of having bone metastasis. PSA-ACT could replace PSA for predicting negative bone scans in a clinical setting in which PSA-ACT is used for monitoring and screening patients for prostate cancer.